• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. J Immunother Cancer. 2020 05; 8(1).

View in: PubMed

subject areas
  • Animals
  • Antineoplastic Agents, Immunological
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Female
  • Hepatitis A Virus Cellular Receptor 2
  • Humans
  • Immunotherapy
  • Injections, Intralesional
  • Injections, Intravenous
  • Lung Neoplasms
  • Lymphocyte Activation
  • Mice
  • Neoplasms, Experimental
  • Oncolytic Virotherapy
  • Oncolytic Viruses
  • Programmed Cell Death 1 Receptor
  • Tumor Microenvironment
  • Urethane

authors with profiles
  • Steven D. Shapiro